The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
|Videos|August 2, 2017
Does Radiotherapy in Unresectable Pancreatic Cancer Add Value?
Author(s)John Ng, MD
This video reviews the conflicting data and perspectives regarding the use of radiotherapy in unresectable pancreatic cancer.
Advertisement
In this video, John Ng, MD, of Weill Cornell Medical College in New York, reviews the conflicting data and perspectives regarding the use of radiotherapy in unresectable pancreatic cancer.
Ng gave a presentation on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Related to this article
The FDA granted breakthrough therapy designation to daraxonrasib/chemotherapy for treatment-naive pancreatic adenocarcinoma based on phase 1/2 trial data.
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
A GDNS protocol did not significantly reduce loss of ASMI compared with usual care during chemoradiotherapy following esophagectomy in esophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5